Emergent BioSolutions Reports First Quarter 2024 Financial Results

First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance ...

Related Keywords

United States ,Canada ,China ,Canadian ,Canton ,Josephc Papa ,Joe Papa ,Assal Hellmer ,Emergent Biosolutions Inc ,Exchange Commission ,Development Expenses ,Company Camden ,Twitter ,Linkedin ,Us Department Of Defense ,Instagram ,Company Canton ,First Quarter ,Net Income ,Diluted Share ,Segment Gross Margin ,Segment Adjusted Gross Margin ,Anthrax Vaccine Adsorbed ,Baltimore Bayview Manufacturing ,Medical Countermeasure ,Commercial Products ,Bavarian Nordic ,Nasal Spray ,Commercial Product ,Ended March ,United States Securities ,Adjusted Gross Margin ,Adjusted Net Income ,Total Segment Revenues ,Total Revenues ,Total Segment Gross Margin ,Total Segment ,Total Segment Adjusted Gross Margin ,Consolidated Statements ,Private Securities Litigation Reform Act ,Botulism Antitoxin Heptavalent ,Reactive Skin Decontamination Lotion Kit ,Senior Unsecured Notes ,Emergent Biosolutions ,Vice President ,Chief Financial ,Months Ended March ,Gross Margin ,Net Loss Forecast ,Adjusted Net Loss ,Forecasted Total Revenues ,Forecasted Total Segment Revenues ,Forecasted Segment ,Markets ,